{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:39:40Z","timestamp":1790883580015,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences\uff08CIFMS\uff09","award":["[2021-I2M-1-003"],"award-info":[{"award-number":["[2021-I2M-1-003"]}]},{"name":"CAMS Innovation Fund for Medical Sciences\uff08CIFMS\uff09","award":["2022-I2M-C&T-A-003"],"award-info":[{"award-number":["2022-I2M-C&T-A-003"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2020MS-0415"],"award-info":[{"award-number":["Y-HR2020MS-0415"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2020QN-0414]"],"award-info":[{"award-number":["Y-HR2020QN-0414]"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2019-0239"],"award-info":[{"award-number":["Y-HR2019-0239"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-128"],"award-info":[{"award-number":["2022-PUMCH-B-128"]}]},{"name":"CSCO-MSD Cancer Re-search Fund","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}]},{"DOI":"10.13039\/501100018538","name":"National Ten-thousand Talent Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03841-z","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T21:01:16Z","timestamp":1727902876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study"],"prefix":"10.1007","volume":"73","author":[{"given":"Shanshan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"2","key":"3841_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","volume":"78","author":"C Sposito","year":"2023","unstructured":"Sposito C, Ratti F, Cucchetti A, Ardito F, Ruzzenente A, Di Sandro S, Maspero M, Ercolani G, Di Benedetto F, Guglielmi A, Giuliante F, Aldrighetti L, Mazzaferro V (2023) Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol 78(2):356\u2013363. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.021","journal-title":"J Hepatol"},{"issue":"5","key":"3841_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW, Advanced Biliary Cancer Working G (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9","journal-title":"Lancet Oncol"},{"key":"3841_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM evidence. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM evidence"},{"issue":"10391","key":"3841_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klumpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A, Investigators K (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"issue":"14","key":"3841_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators ABCT (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"1","key":"3841_CR6","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","volume":"21","author":"SH Tella","year":"2020","unstructured":"Tella SH, Kommalapati A, Borad MJ, Mahipal A (2020) Second-line therapies in advanced biliary tract cancers. Lancet Oncol 21(1):e29\u2013e41. https:\/\/doi.org\/10.1016\/S1470-2045(19)30733-8","journal-title":"Lancet Oncol"},{"key":"3841_CR7","doi-asserted-by":"publisher","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","volume":"31","author":"Z Lwin","year":"2020","unstructured":"Lwin Z, Gomez-Roca C, Saada-Bouzid E, Yanez E, Mu\u00f1oz FL, Im SA, Castanon E, Senellart H, Graham D, Voss M, Doherty M, Lopez J, Ghori R, Kubiak P, Jin F, Norwood K, Chung HC (2020) LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Ann Oncol 31:S1170. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2271","journal-title":"Ann Oncol"},{"issue":"4","key":"3841_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, Wang A, Xie F, Shi W, Yang H, Pan J, Hu K, Guan M, Zhao L, Huo L, Mao Y, Sang X, Wang K, Zhao H (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9(4):414\u2013424. https:\/\/doi.org\/10.21037\/hbsn-20-338","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"3841_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, Wang XY, Sun L, Ge NL, Huang XW, Qiu SJ, Yang XR, Gao Q, He YF, Xu Y, Sun J, Ren ZG, Fan J, Zhou J (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 8(1):106. https:\/\/doi.org\/10.1038\/s41392-023-01317-7","journal-title":"Signal Transduct Target Ther"},{"issue":"15(_suppl)","key":"3841_CR10","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1200\/JCO.2021.39.15_suppl.4099","volume":"39","author":"Z Jian","year":"2021","unstructured":"Jian Z, Fan J, Shi G-M, Huang X-Y, Wu D, Liang F, Yang G-H, Lu J-C, Chen Y, Ge N-L, Ji Y, Hou YY, Sun H-C, Qiu S-J, Ye Q-H, Huang X-W, Shi Y-H, Gao Q, Yang X-R, Wang X-Y (2021) Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial. J Clin Oncol 39(15(_suppl)):4099\u20134099. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4099","journal-title":"J Clin Oncol"},{"key":"3841_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946861","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F (2022) Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China. Front Immunol 13:946861. https:\/\/doi.org\/10.3389\/fimmu.2022.946861","journal-title":"Front Immunol"},{"key":"3841_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu X, Wei S, Zhang L, Tian Y, Gao Z, Jin M, Yan S (2021) Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label. Phase II Study. Front Oncol 11:751391. https:\/\/doi.org\/10.3389\/fonc.2021.751391","journal-title":"Phase II Study. Front Oncol"},{"issue":"5","key":"3841_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ (2019) Toripalimab: First Global Approval. Drugs 79(5):573\u2013578. https:\/\/doi.org\/10.1007\/s40265-019-01076-2","journal-title":"Drugs"},{"issue":"8","key":"3841_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cac2.12068","volume":"40","author":"XL Wei","year":"2020","unstructured":"Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH (2020) A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond) 40(8):345\u2013354. https:\/\/doi.org\/10.1002\/cac2.12068","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"3841_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M (2023) Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34(2):127\u2013140. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506","journal-title":"Ann Oncol"},{"issue":"1","key":"3841_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3841_CR17","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/hep.31862","volume":"74","author":"JG Yoon","year":"2021","unstructured":"Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN (2021) Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1\/Programmed Death-Ligand 1 Blockade Responses. Hepatology 74(4):1914\u20131931. https:\/\/doi.org\/10.1002\/hep.31862","journal-title":"Hepatology"},{"issue":"8","key":"3841_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","volume":"3","author":"DL Rimm","year":"2017","unstructured":"Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II (2017) A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol 3(8):1051\u20131058. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0013","journal-title":"JAMA Oncol"},{"key":"3841_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","volume":"134","author":"M Dietel","year":"2019","unstructured":"Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF, Akita H, Chan OSH, Piperdi B, Burke T, Khambata-Ford S, Deitz AC (2019) Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer 134:174\u2013179. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.012","journal-title":"Lung Cancer"},{"key":"3841_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907055","volume":"12","author":"X Ding","year":"2022","unstructured":"Ding X, Li G, Sun W, Shen Y, Teng Y, Xu Y, Li W, Liu M, Chen J (2022) Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting-A Multi-Center Observational Study. Front Oncol 12:907055. https:\/\/doi.org\/10.3389\/fonc.2022.907055","journal-title":"Front Oncol"},{"issue":"6","key":"3841_CR21","doi-asserted-by":"publisher","first-page":"e002356","DOI":"10.1136\/jitc-2021-002356","volume":"9","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H (2021) Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer 9(6):e002356. https:\/\/doi.org\/10.1136\/jitc-2021-002356","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3841_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-021-07942-1","volume":"21","author":"J Xiao","year":"2021","unstructured":"Xiao J, Li W, Huang Y, Huang M, Li S, Zhai X, Zhao J, Gao C, Xie W, Qin H, Cai S, Bai Y, Lan P, Zou Y (2021) A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer 21(1):282. https:\/\/doi.org\/10.1186\/s12885-021-07942-1","journal-title":"BMC Cancer"},{"issue":"12","key":"3841_CR23","doi-asserted-by":"publisher","first-page":"e1294","DOI":"10.1634\/theoncologist.2019-0236","volume":"24","author":"J Cao","year":"2019","unstructured":"Cao J, Chen L, Li H, Chen H, Yao J, Mu S, Liu W, Zhang P, Cheng Y, Liu B, Hu Z, Chen D, Kang H, Hu J, Wang A, Wang W, Yao M, Chrin G, Wang X, Zhao W, Li L, Xu L, Guo W, Jia J, Chen J, Wang K, Li G, Shi W (2019) An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Oncologist 24(12):e1294\u2013e1302. https:\/\/doi.org\/10.1634\/theoncologist.2019-0236","journal-title":"Oncologist"},{"key":"3841_CR24","doi-asserted-by":"publisher","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research N, Van Allen EM, Cherniack AD, Ciriello G, Sander C and Schultz N (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337 e310. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035","DOI":"10.1016\/j.cell.2018.03.035"},{"issue":"22","key":"3841_CR25","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, Bai H, Tian Y, Wan R, Han M, Cao Y, Xiong L, Liu L, Wang S, Cai S, Mok TSK, Wang J (2018) Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. Cancer Res. 78(22):6486\u20136496. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1814","journal-title":"Cancer Res."},{"key":"3841_CR26","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Biliary Tract Cancers Version 2. 2023. Available online: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf."},{"key":"3841_CR27","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2019.AB060","author":"YY Su","year":"2019","unstructured":"Su YY, Chiang NJ, Lin YJ, Shan YS, Chen LT (2019) AB060. P-31 Complete response to immunotherapy in cholangiocarcinoma with peritoneal metastases and high PD-L1 expression: a case report. Hepatobiliary Surg Nutr. https:\/\/doi.org\/10.21037\/hbsn.2019.AB060","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"3841_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","volume":"49","author":"T Walter","year":"2013","unstructured":"Walter T, Horgan AM, McNamara M, McKeever L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H (2013) Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. European J Cancer. 49(2):329\u2013335","journal-title":"European J Cancer."},{"key":"3841_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646979","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X, Zhao H (2021) The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol 11:646979. https:\/\/doi.org\/10.3389\/fonc.2021.646979","journal-title":"Front Oncol"},{"issue":"47","key":"3841_CR30","doi-asserted-by":"publisher","first-page":"e202309744","DOI":"10.1002\/anie.202309744","volume":"62","author":"Z Rashidijahanabad","year":"2023","unstructured":"Rashidijahanabad Z, Ramadan S, O\u2019Brien NA, Nakisa A, Lang S, Crawford H, Gildersleeve JC, Huang X (2023) Stereoselective Synthesis of Sialyl Lewis(a) Antigen and the Effective Anticancer Activity of Its Bacteriophage Qbeta Conjugate as an Anticancer Vaccine. Angew Chem Int Ed Engl 62(47):e202309744. https:\/\/doi.org\/10.1002\/anie.202309744","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"3841_CR31","doi-asserted-by":"publisher","first-page":"e003214","DOI":"10.1136\/jitc-2021-003214","volume":"9","author":"X Chen","year":"2021","unstructured":"Chen X, Wang D, Liu J, Qiu J, Zhou J, Ying J, Shi Y, Wang Z, Lou H, Cui J, Zhang J, Liu Y, Zhao F, Pan L, Zhao J, Zhu D, Chen S, Li X, Li X, Zhu L, Shao Y, Shu Y (2021) Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer 9(11):e003214. https:\/\/doi.org\/10.1136\/jitc-2021-003214","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3841_CR32","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.3171\/2021.11.FOCUS21604","volume":"52","author":"LG Richardson","year":"2022","unstructured":"Richardson LG, Miller JJ, Kitagawa Y, Wakimoto H, Choi BD, Curry WT (2022) Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. Neurosurg Focus 52(2):E6. https:\/\/doi.org\/10.3171\/2021.11.FOCUS21604","journal-title":"Neurosurg Focus"},{"issue":"18","key":"3841_CR33","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.3390\/ijms231810869","volume":"23","author":"G Brandi","year":"2022","unstructured":"Brandi G, Rizzo A (2022) IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci 23(18):10869. https:\/\/doi.org\/10.3390\/ijms231810869","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3841_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/cancers14010233","volume":"14","author":"SL Csoma","year":"2022","unstructured":"Csoma SL, Bedekovics J, Veres G, Arokszallasi A, Andras C, Mehes G, Mokanszki A (2022) Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing. Cancers (Basel) 14(1):233. https:\/\/doi.org\/10.3390\/cancers14010233","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3841_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/carcin\/bgz134","volume":"40","author":"LE Huang","year":"2019","unstructured":"Huang LE (2019) Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis 40(11):1299\u20131307. https:\/\/doi.org\/10.1093\/carcin\/bgz134","journal-title":"Carcinogenesis"},{"issue":"4","key":"3841_CR36","first-page":"593","volume":"201","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K (2023) Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. eJHaem 201(4):593\u2013796","journal-title":"eJHaem"},{"issue":"1","key":"3841_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.7150\/thno.63417","volume":"12","author":"XY Wang","year":"2022","unstructured":"Wang XY, Zhu WW, Wang Z, Huang JB, Wang SH, Bai FM, Li TE, Zhu Y, Zhao J, Yang X, Lu L, Zhang JB, Jia HL, Dong QZ, Chen JH, Andersen JB, Ye D, Qin LX (2022) Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics 12(1):260\u2013276. https:\/\/doi.org\/10.7150\/thno.63417","journal-title":"Theranostics"},{"issue":"4","key":"3841_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.21037\/jgo.2016.03.05","volume":"7","author":"HO Al-Shamsi","year":"2016","unstructured":"Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM (2016) BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol 7(4):556\u2013561. https:\/\/doi.org\/10.21037\/jgo.2016.03.05","journal-title":"J Gastrointest Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03841-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T07:04:24Z","timestamp":1731740664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03841-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3841"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03841-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) and Ethics Committee (EC) of PUMCH (No. JS-1391). Informed consent was provided by patients or waived by the ethical review committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"249"}}